Undertaking and Scope. Each Party agrees to use Commercially Reasonable and Diligent Efforts to perform its activities detailed in the Development Plans in a professional and timely manner.
Undertaking and Scope. From time to time the Research Management Committee will agree on the general direction of the research to be performed hereunder. The correspondence and other material documenting such agreement are collectively referred to herein as the “Research Plan.” Each party agrees to use its best efforts to perform the activities detailed in the Research Plan, in a professional and timely manner. Onyx agrees to use its best efforts at its cost [*] to (i) develop and transfer to Warner [*] screening assays [*] of the Term of the Research Collaboration for specific targets in the Field selected by the Research Management Committee, (ii) supply protein required to run such screens and (iii) provide for the testing of substantially all of Onyx’s compound library in such screens. Onyx shall not knowingly provide or perform research on any compounds the use of which would require a royalty or other payment to any third party, unless the Research Management Committee agrees that such compound should be provided and the parties agree in writing how such royalty or other payment will be paid. Warner agrees to use its best efforts at its cost (including the cost of any royalties or other amounts payable by Warner to third parties) to (i) screen substantially all of its compound library with such screens provided by Onyx and (ii) conduct medicinal chemistry and animal pharmacology as the Research Management Committee deems appropriate. Promptly after the Effective Date, Onyx and Warner will disclose to each other all information possessed by it relevant to the Field and necessary or helpful to perform the work described in the Research Plan (except to the extent precluded by the pre-existing confidentiality obligations described on Schedule 1 hereto). During the Term of the Research Collaboration, or one year thereafter, the Research Management Committee and either party individually may from time to time declare any compound that meets the definition therefor in Article 1 to be a Collaboration Compound. Notwithstanding the foregoing, neither party will be required to offer the other party any compounds or information relating to compounds that have been identified as candidates for cGLP/cGMP studies on or before the Effective Date, or are hereafter so identified without material application of information provided by the other party or developed pursuant to the Collaboration. Neither party shall be required to screen under this Collaboration or to offer to the other party a...
Undertaking and Scope. Each party agrees to use its best efforts to perform the activities detailed in the Stage I Research Plan attached hereto as Exhibit 1 in a professional and timely manner. Durixx Xxxxx 0, XxxxxXxxx xxxl use its best efforts at its cost (including the cost of any royalties or other amounts owed to third parties by LeukoSite) to develop and transfer to Warner a receptor-ligand screen for IL-8 Inhibitors and (ii) cells containing an IL-8 receptor useful in creating an IL-8 triggered cell based screen for IL-8
Undertaking and Scope. During the first 30 days after the Effective Date, the parties shall work together to develop a plan for the creation and use of the Research Database (a "Research Plan") by the parties. The Research Management Committee will review and approve or modify the general direction of such Research Plan. The Research Plan shall include such correspondence and other material of the parties documenting the parties' work to create the Research Database. At least 90 days before each anniversary of the Effective Date during the Research Term, the parties shall propose to the RMC a Research Plan for the subsequent year's work under the Research Program. The RMC shall review, modify, if appropriate, and amend the Research Plan. Each party agrees to use all reasonable efforts to perform the activities detailed in the Research Plan, in a professional and timely manner.
Undertaking and Scope. Each party agrees to use its best efforts to perform the activities detailed in the Stage 1 Research Plan attached hereto as Exhibit 1 in a professional and timely manner. Durixx Xxxxx 0, XxxxxXxxx xxxl use its best efforts at its cost (including the cost of any royalties or other amounts owed to third parties by LeukoSite) to develop and transfer to Warner (i) a receptor-ligand screen for MCP-1 Inhibitors, and (ii) an MCP-1 triggered cell based screen for MCP-1
Undertaking and Scope. (a) Prior to the earlier of (i) the initial meeting of the Research Management Committee and (ii) in the case of Indication #1, 30 days from the Agreement Date, or in the case of the other Indications, 30 days from the date that the applicable option under Section 6 is exercised by JT, the parties shall work together to agree upon a plan for the creation and use of the Research Databases by the parties for the first year of the Research Program. Such plan shall set forth the schedule of specific activities to be undertaken during the applicable period of the Program Term, the resources to be employed, including the allocation of Scientific FTEs and each scientist's role, the intended acquisition of Samples during such period (and the timing thereof) and the budget for such period. The Research Management Committee will review and, in its discretion, approve or modify the general direction of such plan. Such plan, as approved by the RMC for any year of the Research Program, is referred to herein as the "Research Plan." A timeline of the research to be performed under the Research Plan for Indication #1 and the related staff allocation plan is attached to this Agreement as Schedule 2.1 for reference purposes. At least 90 days before each anniversary of the Effective Date during the Program Term, the parties shall propose to the RMC a Research Plan to govern the further development of the Research Databases during the following year of the Research Program, and the RMC shall review, modify if appropriate, and
Undertaking and Scope. Prior to March 30, 2001, the Parties shall agree --------------------- upon a Research Plan for the first year of the Research Program. Such plan shall set forth the schedule of specific activities to be undertaken during the applicable period of the Research Term, the resources to be employed, including the allocation of Scientific FTEs and each scientist's role, the desired goals to be achieved (and the timing thereof) and the budget for such period. The Research Management Committee will review and, in its discretion, approve or modify the general direction of such plan. Such plan, as approved by the RMC for any year of the Research Program, is referred to herein as the "Research Plan." At least 90 days before each anniversary of the Effective Date during the Research Term, the Parties shall propose to the RMC a Research Plan to govern the further development during the following year of the Research Program, and the RMC shall review, modify if appropriate, and approve such Research Plan by such Curis-Aegera License and Collaboration (Execution Copy) Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.
Undertaking and Scope. For so long as neither Party has Opted Out and not Opted Back In with respect to the applicable Product and/or Region, each Party agrees to use Commercially Reasonable and Diligent Efforts to perform its activities detailed in the Development Plans in a professional and timely manner with respect to each Product, Region and Indication.
Undertaking and Scope. The initial Research Plan covering the 16-month period from September 1, 1999 through December 31, 2000 has been separately agreed to by the Parties. The Research Plan shall be updated annually beginning in the year 2000 and presented [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. to the Steering Committee for approval prior to August 31 of each year preceding the year covered by such budget. Each Party agrees to perform the activities detailed in the Research Plan in a professional and timely manner. The Research Plan shall have the following objectives: (i) to investigate the possibilities for Systemic ONYX-015, and (ii) to investigate two potential therapeutic products - the Pro-Drug Product and the Gene Product - as additional Licensed Products based on incorporation of genes into ONYX-015 or another adenovirus that selectively replicates in and kills cancer cells based on abnormal p53 pathway function.
Undertaking and Scope. The Parties hereby agree to establish and conduct, during the Collaboration Term, a collaborative research program in accordance with a plan (the "Research Plan") and the terms of this Agreement with the goal of developing and commercializing Products. The initial Research Plan for conducting such research program is attached hereto as Exhibit A.
